Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol

Joan T Price, Katie R Mollan, Nurain M Fuseini, Bethany L Freeman, Helen B Mulenga, Amanda H Corbett, Bellington Vwalika, Jeffrey S A Stringer, Joan T Price, Katie R Mollan, Nurain M Fuseini, Bethany L Freeman, Helen B Mulenga, Amanda H Corbett, Bellington Vwalika, Jeffrey S A Stringer

Abstract

Background: Women infected with HIV have a risk of preterm birth (PTB) that is twice that among uninfected women, and treatment with antiretroviral therapy (ART) may further increase this risk. Progesterone supplementation reduces the risk of preterm delivery in women who have a shortened cervix in the midtrimester. We propose to study the feasibility of a trial of vaginal progesterone (VP) to prevent PTB among HIV-infected women receiving ART in pregnancy. Given low adherence among women self-administering vaginal study product in recent microbicide trials, we plan to investigate whether adequate adherence to VP can be achieved prior to launching a full-scale efficacy trial.

Methods and design: One hundred forty HIV-infected pregnant women in Lusaka, Zambia, will be randomly allocated to daily self-administration of either VP or matched placebo, starting between 20 and 24 gestational weeks. The primary outcome will be adherence, defined as the proportion of participants who achieve at least 80% use of study product, assessed objectively with a validated dye stain assay that confirms vaginal insertion of returned single-use applicators. Secondary outcomes will be study uptake, retention, and preliminary efficacy. We will concurrently perform semi-structured interviews with participants enrolled in the study and with women who decline enrollment to assess the acceptability of VP to prevent PTB and of enrollment to a randomized controlled trial.

Discussion: We hypothesize that VP could prevent PTB among women receiving ART in pregnancy. In preparation for a trial to test this hypothesis, we plan to assess whether participants will be adherent to study product and protocol.

Trial registration: ClinicalTrial.gov, NCT02970552.

Keywords: Antiretroviral therapy; HIV; Preterm birth; Progesterone; Sub-Saharan Africa.

Conflict of interest statement

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Participant flow diagram
Fig. 2
Fig. 2
Schedule of study events, visits, and assessments

References

    1. March of Dimes P. Save the Children. WHO . Born too soon: the global action report on preterm birth. Geneva: WHO; 2012.
    1. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162–2172. doi: 10.1016/S0140-6736(12)60820-4.
    1. Joint United Nations Programme on HIV/AIDS. The Gap Report. 2014; . Accessed 14 Mar 2016.
    1. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998;12(18):F241–F247. doi: 10.1097/00002030-199818000-00002.
    1. Rudin C, Spaenhauer A, Keiser O, et al. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med. 2011;12(4):228–235. doi: 10.1111/j.1468-1293.2010.00876.x.
    1. van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc. 2011;14:42. doi: 10.1186/1758-2652-14-42.
    1. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J Infect Dis. 2007;196(4):558–561. doi: 10.1086/519848.
    1. Darak S, Darak T, Kulkarni S, et al. Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India. AIDS Patient Care STDS. 2013;27(3):163–170. doi: 10.1089/apc.2012.0401.
    1. European Collaborative S, Swiss M, Child HIVCS. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14(18):2913–2920. doi: 10.1097/00002030-200012220-00013.
    1. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis. 2012;54(9):1348–1360. doi: 10.1093/cid/cis198.
    1. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21(8):1019–1026. doi: 10.1097/QAD.0b013e328133884b.
    1. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect. 2009;85(2):82–87. doi: 10.1136/sti.2008.032300.
    1. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18(17):2337–2339. doi: 10.1097/00002030-200411190-00019.
    1. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(11):1695–1705. doi: 10.1093/infdis/jis553.
    1. Mazor M, Hershkowitz R, Ghezzi F, et al. Maternal plasma and amniotic fluid 17 beta-estradiol, progesterone and cortisol concentrations in women with successfully and unsuccessfully treated preterm labor. Arch Gynecol Obstet. 1996;258(2):89–96. doi: 10.1007/BF00626029.
    1. Caritis SN, Venkataramanan R, Thom E, et al. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. Am J Obstet Gynecol. 2014;210(2):e121–e126. doi: 10.1016/j.ajog.2013.10.008.
    1. Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38(1):18–31. doi: 10.1002/uog.9017.
    1. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379–2385. doi: 10.1056/NEJMoa035140.
    1. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188(2):419–424. doi: 10.1067/mob.2003.41.
    1. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening G. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357(5):462–469. doi: 10.1056/NEJMoa067815.
    1. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214(2):231–241. doi: 10.1002/path.2276.
    1. Spencer LY, Christiansen S, Wang CH, et al. Systemic immune activation and HIV shedding in the female genital tract. J Acquir Immune Defic Syndr. 2016;71(2):155–162. doi: 10.1097/QAI.0000000000000823.
    1. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(1):38–42. doi: 10.1097/01.qai.0000248352.18007.1f.
    1. Cu-Uvin S, Delong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS. 2010;24(16):2489–2497. doi: 10.1097/QAD.0b013e32833e5043.
    1. Ondoa P, Gautam R, Rusine J, et al. Twelve-month antiretroviral therapy suppresses plasma and genital viral loads but fails to alter genital levels of cytokines, in a cohort of HIV-nfected Rwandan women. Plos One. 2015;10(5):e0127201. doi: 10.1371/journal.pone.0127201.
    1. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–518. doi: 10.1056/NEJMoa1402269.
    1. Rees H, Delany-Moretlwe SA, Lombard C, Barond D, Panchia R, Myer L, Schwartz JL, Doncel GF, Gray G. FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women. Seattle: CROI; 2015.
    1. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Norman JE, Marlow N, Messow CM, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387(10033):2106–16. doi: 10.1016/S0140-6736(16)00350-0.
    1. Doig GS, Simpson SF. Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005;20(2):187–191. doi: 10.1016/j.jcrc.2005.04.005.
    1. van der Straten A, Cheng H, Mensch B, et al. Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis. 2013;40(12):950–956. doi: 10.1097/OLQ.0000000000000053.
    1. O’Reilly M, Parker N. ‘Unsatisfactory Saturation’: a critical exploration of the notion of saturated sample sizes in qualitative research. Qual Res. 2012;13(2):190–7. doi: 10.1177/1468794112446106.
    1. Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82. doi: 10.1177/1525822X05279903.
    1. Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–56. doi: 10.1016/j.contraception.2006.10.012.
    1. Blackwelder WC, Hastings BK, Lee ML, Deloria MA. Value of a run-in period in a drug trial during pregnancy. Control Clin Trials. 1990;11(3):187–198. doi: 10.1016/0197-2456(90)90013-R.
    1. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338(11):701–705. doi: 10.1056/NEJM199803123381101.
    1. Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1993;329(17):1213–1218. doi: 10.1056/NEJM199310213291701.
    1. Rouse DJ, Caritis SN, Peaceman AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357(5):454–461. doi: 10.1056/NEJMoa070641.
    1. Caritis SN, Rouse DJ, Peaceman AM, et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol. 2009;113(2 Pt 1):285–292. doi: 10.1097/AOG.0b013e318193c677.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere